S*BIO
-
S*BIO to initiate global phase 3 clinical trials of its novel JAK2 inhibitor
S*BIO explores partnering opportunities for advancement of its JAK2 program.
S*BIO | 25 October 2011
-
S*BIO initiates phase 2 clinical trial of its JAK2 inhibitor
S*BIO Pte Ltd announced that it has dosed the first 10 patients in a phase 2 clinical trial of its novel JAK2 inhibitor SB1518 in the US and Canada for the treatment of advanced lymphoid malignancies. This multi-center, open-label, study is design…
S*BIO | 14 April 2011
-
S*BIO presents novel dual inhibitor at American Association of Cancer Research conference
S*BIO Pte Ltd announced that its novel dual mTOR/PI3 Kinase inhibitor SB2343 demonstrated excellent pharmacokinetic/pharmacodynamic (PK/PD) properties leading to significant anti-tumor efficacy in rapamycin-sensitive and resistant xenograft models. I…
S*BIO | 08 March 2011
-
S*BIO's fourth compound enters phase 1 clinical trial
A fourth novel, potential bestin-class compound discovered and developed by S*BIO has entered a phase 1 clinical trial. The initiation of the study for S*BIO’s oral multi-kinase inhibitor, SB1317 or TG02, in patients with advanced/refractory he…
S*BIO | 21 January 2011
-
EU grants SB1518 orphan drug designation
The European Commission (EC) has granted orphan drug designation to S*BIO SB1518, its potent and orally active JAK2 inhibitor for the treatment of primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF) and postessential thrombocyt…
S*BIO | 04 November 2010
-
Phase 2 clinical trial for SB939
S*BIO started a phase 2 clinical trial of SB939, its novel orally-active HDAC inhibitor, in patients with recurrent or metastatic prostate cancer (HRPC). The trial is sponsored by the NCIC Clinical Trials Group and will be conducted at eight clinica…
S*BIO | 17 October 2010
-
Mitsui Ventures invests US$5 million in S*BIO
A US$5 million investment by Mitsui Ventures will support the continued development of S*BIO’s clinical programs. “Mitsui Ventures’ financing commitment reflects the international investment community’s strong interest in our track recor…
S*BIO | 01 October 2010
-
S*BIO Completes Patients Enrollment in Phase 2 Clinical Trials
S*BIO announces that it has completed enrollment of patients in two separate Phase 2 clinical trials for its potent and orally-active JAK2 inhibitor SB1518 at multiple clinical sites in the US and Australia for the treatment of myelofibrosis (MF). …
S*BIO | 14 June 2010
-
S*BIO and Onyx Pharmaceuticals Expand Collaboration for JAK2 Inhibitors
S*BIO and Onyx Pharmaceuticals have announced the expansion of their development collaboration and option and license commercialization agreement for the former’s JAK2 inhibitors, SB1518 and SB1578, also known as ONX 0803 and ONX 0805, respectively…
S*BIO | 19 May 2010
-
S*Bio: Jak2 Inhibitor Demonstrates Safety in Studies for Myeloproliferative Disorder
S*BIO has announced data presentations on its oral JAK2 inhibitor, SB1518. Data will be presented on the clinical results from the Phase 1 dose-escalation trial of SB1518 detailing its safety, tolerability and pharmacokinetic/pharmacodynamic (PK/PD) …
S*BIO | 09 December 2009
